

Patient Card

Erivedge could harm or cause the death of the unborn child.

Female patients of childbearing potential must:

- Always use two of the recommended contraception methods (one of them must be a barrier method, and the other must be a highly effective method) during treatment and for 24 months after taking the final dose (please see the Erivedge Pregnancy Prevention Programme brochure for further information)
- Take a pregnancy test every month in order to monitor for pregnancy

Male patients must:

- Always use a condom (with spermicide if possible) when having sexual intercourse with a female partner during treatment and for 2 months after taking the final dose
- Not donate sperm during treatment or during the 2 months after taking the final dose

Speak with your doctor immediately if your or your sexual partner's menstrual period is delayed, if pregnancy is suspected or if there is pregnancy.

- Female patients - Consult with your doctor if you suspect that you are pregnant during treatment with Erivedge or during the 24 months after you take your final dose
- Male patients - Consult with your doctor if your partner suspects that she is pregnant while you are taking Erivedge or during the 2 months after you take your final dose

All patients must:

- Do not donate blood during treatment or during the 24 months after taking your final dose.
- Do not give this medicine to anybody else.

Precise instructions can be found in the drug leaflet on the Ministry of Health website or on the Roche website at www.roche.co.il

Side effects can be reported to the Ministry of Health using the online form for reporting side effects that can be found on the homepage of the Ministry of Health website www.health.gov.il or by entering the link:

<https://sideeffects.health.gov.il/>
or to Roche by email to Israel.DrugSafety@roche.com

Telephone numbers in case of emergency: _____

The format of this card and its contents were approved by the Ministry of Health in May 2021